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PERENCATAN EPHA2 siRNA KE ATAS SEL TUMOR OTAK MALIGNAN 
 
ABSTRAK 
 
 Tumor otak malignan adalah salah satu jenis tumor yang paling ganas dan 
membawa maut dengan kadar jangka hayat hanya 9-12 bulan. Kadar ekspresi gen 
EphA2 yang tinggi telah dikaitkan dengan perkembangan dan percambahan tumor 
otak malignan. Untuk mengkaji peranan EphA2 dalam pembiakan sel tumor otak 
malignan manusia, perencatan ekspresi gen EphA2 telah dijalankan dengan 
menggunakan siRNA. Dalam kajian ini, tiga kepekatan siRNA 12.5 nM , 25 nM dan 
37.5 nM telah digunakan untuk mensasarkan gen EphA2 di dalam sel U87 secara in 
vitro. Real-Time PCR telah dijalankan untuk menganalisis tahap ekspresi gen EphA2 
diikuti oleh ujian MTS untuk mengkaji perubahan daya tahan sel U87. Berdasarkan 
hasil pemerhatian dari ekspresi gen EphA2 menunjukkan bahawa kadar perencatan 
sangat signifikan dalam kumpulan sel yang dirawat dengan ketiga-tiga kepekatan 
siRNA (p < 0.05). Peratusan tertinggi kadar perencatan gen EphA2 dapat diperhatikan 
pada kepekatan 12.5 nM (73.6%), diikuti oleh 37.5 nM (63.1%) dan 25 nM (45%). 
Berdasarkan analisis MTS, kadar penurunan daya tahan sel U87 dapat diperhatikan 
dalam kumpulan yang dirawat dengan EphA2 siRNA  25 nM dan 37.5 M selepas 48 
jam proses transfeksi. Pengurangan sebanyak 50.1% dan 22.2% kadar daya tahan sel 
U87 masing-masing dapat dilihat dalam sel yang dirawat oleh EphA2 siRNA 25 nM 
dan 37.5 nM. Kajian sebelum ini menunjukkan bahawa EphA2 secara signifikannya 
terlibat didalam aktiviti daya tahan sel tumor otak malignan. Walaubagaimanapun, di 
dalam kajian ini, hubungan diantara kadar perencatan daya tahan sel U87 dengan kadar 
xiii 
 
perencatan ekspresi gen EphA2 adalah tidak signifikan. Kesimpulannya, kajian ini 
menunjukkan bahawa transfeksi yang dijalankan oleh ketiga-tiga kepekatan EphA2 
siRNA adalah signifikan untuk merencatkan ekspresi EphA2 pada tahap mRNA, 
namun begitu, ianya tidak konsisten dengan kadar perencatan aktiviti daya tahan sel 
U87. 
Kata kunci: tumor malignan, EphA2, siRNA, percambahan sel 
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EPHA2 siRNA SILENCING ON MALIGNANT GLIOMA CELLS 
 
ABSTRACT 
 
 Malignant glioma is one of the most aggressive type of solid tumours which is 
highly fatal with median survival rate of only 9-12 months. Recently, overexpression 
of EphA2 has been correlated with the development and tumour progression of 
malignant glioma. In order to examine the role of EphA2 in malignant glioma cells, 
inhibition of EphA2 gene expression was carried out using small interfering RNA 
(siRNA). In this study, siRNA targeting EphA2 gene was used to transfect U87 cells 
in vitro at three different concentration 12.5 nM, 25 nM and 37.5 nM. Real-Time PCR 
was used to analyse the EphA2 gene expression levels followed by MTS assay in order 
to examine the changes in cell viability of U87 cells. Evaluation of the gene expression 
showed that, significant inhibition of the EphA2 gene expression was observed in 
groups of cells treated with all 3 concentration of siRNA (p < 0.05). The highest 
knockdown percentage of EphA2 gene was observed at concentration of 12.5 nM 
(73.6%), followed by 37.5 nM (63.1%) and 25 nM (45%). Based on MTS assay 
analysis, a decline in cell viability of U87 cells was observed in groups treated with 
EphA2 siRNA 25 nM and 37.5 nM after 48 hours post transfection. Reduction of     
50.1 % and 22.2 % of U87 cells viability was observed in cells treated with EphA2 
siRNA 25 nM and 37.5 nM respectively. Recent evidences have shown that EphA2 
significantly involves in mediating viability activities of malignant glioma cells. 
Nevertheless, in this study, the correlation between inhibition of U87 cells viability 
and EphA2 gene expression knockdown was found not to be significant. In conclusion, 
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this study demonstrated that transfection with all three concentration of EphA2-
siRNAs significantly inhibited EphA2 expression at the mRNA level, however it did 
not consistently suppresses the viability of U87 cells. 
 
Keyword: malignant glioma, EphA2, siRNA, cell proliferation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
 
INTRODUCTION 
 
Study background 
 
Malignant glioma is known as the most severe form of primary brain tumour 
(Price and Chiocca, 2014). Every year, around 1 ~ 5 cases in 100,000 people are 
diagnosed with malignant glioma (Dolecek et al., 2012) with poor prognosis  and low 
median survival rate (Hamisch et al., 2017). Despite various advancements in the 
treatment strategy for treating malignant glioma, prognosis of the patients remains 
poor. Most of the patients die due to recurrence of the tumour. 
 
In normal condition, erythropoietin-producing hepatocellular receptor A2 
(EphA2) receptor tyrosine kinase plays an important role in controlling multiple 
physiological processes to maintain homeostasis inside the cells (Zhou and Sakurai, 
2017). However, in malignant glioma tumours, it has been reported that, elevated 
expression of EphA2 was frequently observed, and plays a critical role in oncogenic 
signalling involving proliferation, angiogenesis, metastasis of tumour (Hafner et al., 
2004; Shen et al., 2014). It is also positively correlated with poor diagnosis of the 
patients (Diamond et al., 2017). 
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Growing evidences show that gene silencing via siRNA approach has a great 
therapeutic potential for treating malignant glioma in order to improve the survival 
rate of the tumour patients. siRNA can improve the median survival rate of malignant 
glioma patients by blocking targeted EphA2 mRNA and subsequently silencing the 
expression of EphA2 in the tumour cells. Silencing of EphA2 will leads to lower 
expression of EphA2 resulting in the decrease of cell proliferation of malignant 
glioma. Due to siRNA sensitivity and feasibility technique to knock down the 
expression of a wide range of genes, it provided a suitable platform for various studies 
to be carried out. Thus, EphA2 comes into sight as a future therapeutic target to curb 
the development of malignant glioma tumours. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Brain tumour 
2.1.1 Classification, risk factors and clinical presentations of brain tumours. 
 
Brain tumour can be defined as an abnormal growth of cells that occurs in any 
part of tissue inside the cranium including the brain, skull, meninges, cranial nerves, 
pituitary gland and pineal gland (Ness, 2013). Brain tumour can be classified into two 
types which are primary and secondary (metastatic) brain tumours. Primary brain 
tumour generally develops from the brain cells itself and does not spread to other parts 
of the body. The tumour appears in either malignant or benign form. Meanwhile for 
secondary brain tumour, it spreads to the brain from other parts of the body and always 
in malignant form. According to World Health Organization (WHO), brain tumours 
can be classified into four grades and it is based on the rate of tumour growth, similarity 
tumour to normal cells, presence or vascularity and necrotic cell in the tumour cells 
(Louis et al., 2016) . Usually, grade I tumours grow very slow and can be cured by 
surgery alone, whereas grade II tumours have the potential to invade adjacent normal 
cells and it may be reoccur again with higher grades of malignancies (Banerjee and 
Nicolaides, 2017). In contrast, for grade III tumours, it usually actively produce 
abnormal cells that can penetrate adjacent cells. Meanwhile, grade IV tumours are the 
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most malignant with rapid infiltration and proliferation to adjacent cells and have a 
central area of necrosis (Chang et al., 2017). Besides that, these tumours will form new 
blood vessel in order to maintain their rapid growth and the most common example of 
highly angiogenic brain tumours are grade III and grade IV tumour. The example of 
grade IV tumour is glioblastoma multiforme (GBM) which referred as malignant 
glioma. Brain tumours classification is illustrated below in Figure 2.1. 
 
Figure 2.1: Classification of brain tumours based on World Health Organization 
(WHO). (Adapted from Louis et al., 2016). 
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There are many factors that can lead to development of brain tumours like 
ionizing radiation, virus infections, genetic abnormalities and other environment 
exposures. As reported by Ellor et al (2014), ionizing radiation is known as one of the 
factor that can enhanced risk of glioma development. For example, after several years 
of therapeutics radiation for another tumour like astrocytoma, radiation-induced 
glioblastoma might be occurred (Ellor et al., 2014; Johnson et al., 2015). Besides that, 
exposure toward other environmental condition such as smoking, pesticides, vinyl 
chloride and synthetic rubber manufacturing have been less associated with the 
development of glioma. Whereas, non-ionizing radiation from cell phones and 
formaldehyde have not been proven yet to caused glioblastoma multiform (Bondy et 
al., 2008; Alifieris and Trafalis, 2015). It has been reported that, increased risk of 
glioma development can be found in certain genetic diseases such as retinoblastoma, 
Turcot syndrome, Li-Fraumeni syndrome, tuberous sclerosis, neurofibromatosis 1 and 
2, however less than 1% of glioma patients aware about their hereditary disease (Ellor 
et al., 2014). 
 
Brain tumour patients may have a variety of signs and symptoms. Primary 
brain tumours symptoms are based on type, rate of growth and location of the tumour 
(Stupp et al., 2014). Gliomas symptoms can occur directly which is by compressing 
the area of the brain or indirectly by enhancing the intracranial pressure which may 
lead to alteration of mental function, vomiting, nausea, seizure and headache (Chang 
et al., 2005). About 15-95% brain tumours patients have at least one seizure symptoms 
during their illness and most of low-grade gliomas patients will easily get seizures 
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rather than glioblastoma multiform (Grade IV) patients. (Chan et al., 2016). The 
histology of the tumours, location and patient age are usually correlated with seizure 
condition. For example, patient with age 30 years and above will commonly get 
seizures often and based on histological diagnosis, about 62% mixed gliomas, 53% 
oligodendrogliomas and 42% astrocytomas patients experienced seizures (Liigant et 
al., 2001; ENGLOT et al., 2016) 
 
2.2 Malignant glioma 
2.2.1   Incidence and symptoms of malignant glioma 
 
Malignant glioma may lead to a progressive destruction of brain tissue due to 
its characteristics which are highly aggressive and invasive growth of tumours (Louis 
et al., 2016). The most common primary malignant glioma consisting of 16% of all 
primary brain and central nervous system neoplasm is known as glioblastoma 
multiforme (GBM) (Thakkar et al., 2014). Based on a study reviewed in Sarawak from 
January 2009 until December 2012, the incidence rate for malignant glioma in 
Malaysia was found to be 4.6 per 100,000 population per year (Lee et al., 2014). 
Meanwhile, the incidence rate of malignant glioma in United States of America is 
about 3.2 per 100,000 population  (Davis, 2016). Until now, malignant glioma still 
remains as untreated diseases with low median survival rate which is around 10 - 15 
months (Koshy et al., 2012; Omuro and DeAngelis, 2013). Besides brain, malignant 
glioma can also emerged in other parts of the central nervous system including brain 
stem, cerebellum and spinal cord. Almost sixty-one percent of all primary malignant 
gliomas develop in the four lobes of the brain such as 25% in frontal lobe, 20% in 
7 
 
temporal lobe followed by 13% in parietal lobe and 3 % in occipital lobe (Davis, 2016). 
Malignant glioma is originally thought to derive from glia cells. However, based on 
the evidences provided by recent studies, it is suggested that the tumours appear from 
multiple cell types with neural stem cell properties and they are differentiated from 
stem cell to neuron to glia (Phillips et al., 2006; Ligon et al., 2017) 
 
Symptoms of malignant glioma depend on the type, location and rate of tumour 
growth which can occur directly or indirectly. Malignant glioma can cause symptoms 
directly by invading or compressing certain area of the brain. Stress on the pariental 
lobes or sensory cortex may lead to disability to process complex sensory input which 
may results in agraphesthesia, astereognosis,  or difficulties two- point discrimination, 
tactile localization, loss of word recognition and language comprehension (Hill et al., 
2002). At the same time, symptoms of malignant glioma can occur indirectly by 
increasing the intracranial pressure in the brain which may lead to headaches, blurred 
vision, nausea and vomiting. Besides that, pressure in frontal lobe of  malignant glioma 
may lead to changes of personality and mental status (Antunes et al., 2017) which 
result in poor attention span, failure of memory, lack of concern and judgement and 
social inappropriateness. Compression in frontal lobe of dominant hemisphere can 
give impact in Broca’a area and then lead to motor dysphasia, whereas, glioma on 
Wernicke’s area result in aphasia or dysphasia.  In addition, malignant glioma in 
temporal lobes may contribute to partial complex seizures, contralateral hemianopsia 
and loss of consciousness. Presence of malignant glioma in occipital lobes areas 
usually associated with visual disturbances like alexia, disability to focus on objects 
and inability to recognize faces or colours (Omuro and DeAngelis, 2013).  
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2.2.2 Molecular pathogenesis of malignant glioma  
 
 Malignant gliomas originate from neural progenitor cells and likely occur due 
to alteration of chromosomal regions and the deregulation of growth-factor signalling 
pathways (Ocvirk and Mesti, 2016). Glioblastomas which is regarded as the most 
common type of malignant glioma can be divided into two main subtypes which are 
based on basis of biological and genetic differences. Generally, primary malignant 
gliomas occur in patients older than 50 years old and are identified by amplification or 
mutation of EGFR, deletion on chromosome 10 of the phosphatase and tensin 
homologue (PTEN), deletion of p16 and loss of heterozygosity of chromosome 10q 
(Aldape et al., 2015). Meanwhile, secondary malignant gliomas develop in younger 
patients as low-grade or anaplastic astrocytomas and it take several years before it 
convert into malignant gliomas. It can be described based on loss of heterozygosity of 
chromosome 10q (LOH), overexpression of the platelet derived growth factor receptor 
(PDGFR), mutations of tumour-suppressor gene (p53) and abnormalities in 
retinoblastoma (Rb) pathways and p16 (Wen and Kesari, 2008). The characteristics of 
high-grade oligodendrogliomas are recognized by the loss of chromosomes 1p and 19q 
in 50% to 90% of patients and the progression from low-grade to anaplastic 
oligodendroglioma is related with defects in cell cycle pathways involving Rb, p53 
and PTEN (Louis et al., 2007; Louis et al., 2016). The alterations of genes that are 
mostly discovered in malignant gliomas are summarized in Table 2.1 (Schwartzbaum 
et al., 2006). 
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Table 2.1: The mostly discovered genes alterations in malignant gliomas. (Adapted 
from Schwartzbaum et al., 2006).  
 
Type of alteration Candidate gliomas genes 
 
Gains 
 
 
-Receptor interacting protein kinase 5 (RIPK5) 
-Mouse double minute 4 (MDM4), Mouse double minute 2 
(MDM2), 
-Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit 
type 2 beta (PIK3C2B) 
-Epidermal growth factor receptor (EGFR) 
-Cyclin-dependent kinase 4 (CDK4) and others 
 
 
          Deletions 
 
 
-NIMA-related kinase 1 (NEK1),  
-Tumour protein 53 (p53) 
-BRAF 
-Neurofibromatosis type I (NF1) 
-Isocitrate dehydrogenase 1 (IDH 1) 
-Cyclin-dependent kinase inhibitor 2A (CDKN2) 
-Phosphatase and tensin homolog (PTEN) 
-O-6-methylguanine-DNA methyltransferase (MGMT) 
-Retinoblastoma 1 (RB1) 
-Glioma tumor suppressor candidate region gene 1 
(GLTSCR1), GLTSCR2, ligase I, DNA, ATP-dependent 
(LIG1), cytohesin 2 (CYTH2), integrase interactor 1 (INI1) 
-between cyclin-dependent kinase inhibitor 1C (CDKN1C) 
and related RAS viral (r-ras) oncogene homolog 2 (RRAS2) 
 
 
 
 
Dysregulation of growth-factor signalling pathways are commonly involving 
EGFR and PDGFR. It can occur via genetic and epigenetic mechanisms such as 
amplification, deletion, gene mutation, methylation or demethylation, gains or losses 
of whole or partial chromosome and transcriptional interference (Figure 2.2). Both of 
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these ligands commonly expressed in malignant glioma and actively involved in glial 
development by creating an autocrine loop that trigger proliferation of the tumour 
(Jones and Holland, 2011). Besides that, growth factor-receptor signalling via 
intermediate signal transduction generators activated transcriptional programs for 
survival, invasion, angiogenesis and proliferation. Usually, it will be activated by 
growth factors like phosphatidylinositol 3-kinase (PI3K)-Akt- mammalian target of 
rapamycin (mTOR) pathways which involved in the inhibition of apoptosis and 
cellular proliferation and Ras-mitogen activated protein (MAP) kinase pathways 
which involved in cell cycle progression and proliferation. On the other hands, 
PDGFR, EGFR and VEGF-receptor (VEGFR) pathways also involved in promoting 
multipotent stem cells proliferation through normal development of nervous system 
(Thakkar et al., 2014). 
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Figure 2.2: Dysregulation of growth-factor signalling pathways. Vascular endothelial 
growth factor (VEGF) are expressed in all high-grade gliomas. DCC indicates deleted 
in colorectal carcinoma, EGFR- epidermal growth factor receptor, LOH- loss of 
heterozygosity, MDM2 –murine double minute 2, PDGFR- platelet-derived growth 
factor receptor, PI3K- phosphatidylinositol 3-kinase, PTEN-phosphatase and tensin 
homologue and RB- retinoblastoma.(Modified from Cohen et al., 2013; Aldape et al., 
2015). 
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2.2.3 Current treatments of malignant glioma 
 
 Surgical resection, radiotherapy and chemotherapy are known as the standard 
treatments for malignant gliomas. The advantages of maximal surgical resection are, 
it can decrease the symptoms from mass effect and provides tissue for molecular 
studies and histological diagnosis (Ahmed et al., 2014). In addition, advancement in 
surgical resection like functional MRI, CT scans, diffuse tensor imaging (DTI) and 
fluorescence-guided surgery can enhance the safety of surgery and improved the 
extend of resection than can be achieved. However, with advances in surgery 
procedures, the prognosis for malignant glioma patients especially glioblastoma 
multiform remain poor with the median survival rate less than 15 months (Thakkar et 
al., 2014). This is due to some limitations such as surgical procedure are likely to cause 
damage to normal tissue, misinterpretation of fMRI results due to neurovascular 
uncoupling and the location of the tumour is unreachable (Bush et al., 2017). 
 
 Occasionally, when surgical resection is impossible, radiotherapy with an 
external beam were chosen as the initial treatment for malignant glioma (Juratli et al., 
2013). Besides that, in 1990, DNA alkylating agents which known as temozolomide 
(TMZ) has been approved as a chemotherapy agent for malignant glioma treatment by 
Food and Drug Administration (FDA) (Price and Chiocca, 2014).  TMZ has the ability 
to pass through the blood brain barrier (BBB). Several studies involving several 
chemotherapeutic agents claimed that, TMZ is a drug that can increased median 
survival rate in malignant glioma patients (Urbańska et al., 2014). According to 
randomized phase III trial shows that, the combination of radiotherapy treatment with 
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TMZ enhanced median survival rate from 12.1up to 14.6 months compared with 
radiotherapy alone (Ocvirk and Mesti, 2016). Moreover, phase III study involving 573 
patients and 85 centres conducted by National Cancer Institute of Canada Clinical 
Trials Group (NCIC) and European Organisation for Research and Treatment of 
Cancer (EORTC) shows that TMZ can be used as a treatment for malignant glioma 
due to improvement in the survival rates from 10 % (radiotherapy alone) up to 27 % 
(radiotherapy with TMZ) (Stupp et al., 2005; Ellor et al., 2014). 
 
 Another chemotherapy agent for malignant glioma is known as nitrosourea 
(e.g: carmustine, lomustine and nimustine). They are alkylating agents and lipid 
soluble which have the ability to pass the BBB successfully. They can be used through 
oral intake, intra- arterial delivery and acts as a wafer in treatment of malignant glioma. 
For example, the biodegradable polymers containing carmustine were implanted into 
the tumour bed after malignant glioma resection. The aim of carmustine treatment is 
to kill the residual tumour cells. Based on a randomized, placebo-controlled trials of 
carmustine treatment in malignant glioma patients, the median survival increased from 
11.6 months up to 13.9 months and this survival rate was maintained around 2-3 years 
(Westphal et al., 2006; Chen et al., 2017).  
 
However, there are some disadvantages of radiotherapy and chemotherapy 
treatment of malignant gliomas. The most common and immediate side effects of 
radiotherapy are hair loss, weakness, headache, fever, vomiting, nausea and scalp 
redness (Charnley et al., 2009; Ellor et al., 2014; Pourgholi et al., 2016). Meanwhile, 
cytotoxic drugs for chemotherapy usually lead to gastrointestinal effects, headaches, 
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dizziness and fatigue. Besides that, intra-arterial administration of nitrosoureas like 
carmustine has also associated with acute neurotoxicity such as confusion and seizures 
(Dropcho, 1999; Philip-Ephraim et al., 2012). 
 
2.3 Eph family receptors 
 
The biggest subfamily of receptor tyrosine kinases (RTKs) known as Eph 
receptors (Ephs) (Himanen and Nikolov, 2003; Tandon et al., 2011). Eph receptors 
consists of 15 members and they are classified into two groups which is EphA (EphA1-
EphA9) and EphB (EphB1-EphB6). EphA receptors normally tether all A-type 
ephrins, meanwhile EphB receptors tether to all B-type ligands. However, there are 
some exceptions, for example EphA1 mainly binds to ephrinA 1and EphA4 binds with 
both ephrinA and ephrinB, followed by ephrinA5 binds to EphA and EphB receptors 
(Figure 2.3) (Mosch et al., 2010). Eph receptors depend on their binding affinity for  
their ligands, Ephrins (Eph receptor interaction protein) (Clifford et al., 2008; Xi et 
al., 2012). According to Hirai et al (1987), the first cloned of Eph gene was 
encountered  in 1985 and a few years later, the first ephrin ligands was found in cancer 
cells (Grumolato and Aaronson, 2017). The connection between Ephs and its ephrin 
ligands is occurred due to the activation of bidirectional and transducer signalling 
cascades. Eph receptors and its ligands plays an important roles in biological functions 
such as involved in cell proliferation, angiogenesis, synaptic plasticity, tissue-border 
formation, axon guidance, development of the nervous system and embryonic 
patterning (Kullander and Klein, 2002; Lodola et al., 2017).  
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Figure 2.3: Interactions of Eph receptors and ephrin ligands. (Modified from Mosch et 
al., 2010).  
 
2.3.1 EphA2 receptor 
 
  Several studies demonstrated that increased level of EphA2 can be found in 
various human tumours such as in carcinoma of prostate, colon, breast, pancreas 
(Chang et al., 2008), ovaries, gastrointestinal tract oesophagus, liver, thyroid (Karidis 
et al., 2011) and malignant glioma (Wykosky et al., 2007).  According to Lindberg 
and Hunter (1990), EphA2 was discovered in 1990 via screening process of human 
epithelial (Hela cells) cDNA library by using a degenerative oligonucleotide probe 
against the amino acid sequence HRDLAAR. Amino acid sequence HRDLAAR is a 
highly conserved region among tyrosine kinases (Lindberg and Hunter, 1990). At first, 
EphA2 was known as epithelial cell kinase (eck) due to its expression in the majority 
of epithelial cells. The human EphA2 gene consists of 90% amino acid sequence 
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homology to the mouse EphA2. It encodes for a receptor tyrosine kinase of 976 amino 
acids with molecular weight of 130 kDa and located on chromosome 1.  
 
Ruiz and Robertson (1994) reported that, EphA2 gene was expressed in various 
regions during human development and it was supported with the study by Mori et al 
(1995). During early embryogenesis, expression of EphA2 gene was detected in the 
hindbrain and distal area of primitive streak especially in rhombomere 4 , while the 
EphA2 expression was decreased in the nervous system during late embryogenesis 
(Mori et al., 1995). In adult stage, the EphA2 gene expression was observed in the 
spleen and brain with moderate levels (Lindberg and Hunter, 1990). However, no 
EphA2 expression was found in thymus, skeletal muscle, heart, liver or testes. 
 
2.3.1.1 Structures of EphA2 receptor 
 
The structure of extracellular domain Eph receptors contains two fibronectin 
type III repeats, also known as ligand-binding globular domain and cysteine-rich 
region. Besides that, the cytoplasmic part of Eph receptors can be classified into four 
functional units such as sterile α-motif (SAM), PDZ-Domain binding motif and two 
tyrosine residues of juxtamembrane. SAM domain contains about ~ 70 amino acids 
and it can form dimers and oligodimers, whereas, PDZ-binding motif contains binding 
sequence like hydrophobic residue and located in the carboxy-terminal 4-5 amino 
acids residues. During binding, ephrin A generally attaches to the cell membrane 
through a glycosyphosphatidylinositol (GPI) anchor (Tandon et al., 2011; Xi et al., 
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2012). The examples of the structures of EphA2 receptor and its ephrin ligands (Ephrin 
A1) are illustrated below in figure 2.4. 
 
 
 
Figure 2.4: Binding of Eph receptor (EphA2 receptor) and its ephrin ligands (Ephrin 
A1). (Modified from Xi et al., 2012). 
 
Ephrin A1 Ligand 
Ephrin A1 binding domain 
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2.3.2 Roles of EphA2 in cancer development 
 
 EphA2 receptors and its ligand (ephrin A1) play important roles in 
physiological and pathophysiological process like proliferation, migration and 
invasion. Besides that, they are also involved in angiogenesis and tumour 
neovascularization (Xi et al., 2012). Angiogenesis can be defined as the growth and 
formation of new blood vessels from existing blood vessels (Hanahan and Folkman, 
1996; Coelho et al., 2017). It is important for metastasis and tumour growth processes 
because it provide the tumour with oxygen, growth factors and nutrients. Previous 
study reported that,  angiogenesis process in malignant glioma is modulated by EphA2 
(Maragoudakis et al., 2012). According to in vitro and in vivo studies conducted in 
2008 and 2009, EphA2 enhanced vascular (blood vessels) permeability via 
phosphorylation of claudins (Larson et al., 2008; Miao and Wang, 2009a). Claudins 
are tight junction membrane proteins which plays a role as paracellular barriers to 
control the movement of molecules in the intracellular space between the epithelium 
cells (Günzel and Alan, 2013). Besides, further study revealed that, high expression of 
EphA2 was positively correlated with VEGF expression during in angiogenesis 
process (Sawamiphak, 2010) in human breast cancer, Kaposi sarcoma, and squamous 
cell carcinoma of the tongue (Shao et al., 2008). 
 
 Up-regulation of EphA2 are found in most invasive tumour cells such as in 
glioblastoma, ovarian cancer , melanoma, prostate cancer, breast cancer, liver cancer,  
and oesophageal squamous cell carcinoma (Tandon et al., 2011). Some study stated 
that, high expression of EphA2 is sufficient to cause tumorigenesis by increasing the 
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proliferation and migration activities of the cells (Zelinski et al., 2001). It is also 
reported that, high expression of EphA2 receptors lead to high in cancer tumour 
invasive behaviour (Ruoslahti, 1999; Ribatti and Nico, 2016). Previous studies in 2005 
reported that, EphA2 was highly expressed in malignant glioma especially in 
glioblastoma multiforme (Wykosky et al., 2005) which suggested that EphA2 plays 
an important role in neovascularisation (Wu et al., 2011). In addition, overexpression 
of EphA2 has also been correlated with proliferation, pathological grade and apoptosis 
in astrocytic brain tumours (Li et al., 2007). 
 
  Previous studies claimed that, the inhibition of EphA2 caused delay in tumour 
growth of mice xenografts (Li et al., 2010). Besides that, inhibition of EphA2 also 
decreased FAK phosphorylation which led to inhibition of integrin-mediated cell 
adhesion, migration, proliferation and cell spreading (Miao and Wang, 2009b; Mosch 
et al., 2010). It is known that integrins plays a crucial roles in the mediation of cell 
adhesion, fibronectin deposition and cell anchorage. Moreover, integrins directly 
affect cell motility, proliferation and invasion which contribute to metastasis and 
formation of tumours (Maulik et al., 2002; Surawska et al., 2004; Wykosky and 
Debinski, 2008).  
 
The roles of EphA2 in normal versus cancer cell are shown below in Figure 2.5. 
In normal condition, binding between EphA2 receptor and its ligands led to EphA2 
phosphorylation and caused degradation of EphA2 resulting in lower expression of 
EphA2. This phosphorylation process was important for normal signalling pathways 
such as MAPK and Akt which involved in cell differentiation, proliferation and 
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migration. Meanwhile, in cancer condition, EphA2 failed to interact with its ligands 
led to accumulation of the un-phosphorylated form of EphA2 in the cells. This 
stimulated oncogenic signalling pathways which increased angiogenesis, proliferation 
and metastasis process of the cells and promote tumorigenicity (Tandon et al., 2011). 
 
 
 
 
 
 
Figure 2.5: The role of EphA2 in normal versus cancer cell. (Modified from Tandon 
et al., 2011). 
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2.4 Small interfering RNA (siRNA) 
2.4.1  Structure of siRNA 
 
Small interfering RNA (siRNA) is known as silencing RNA or short interfering 
RNA. It is double-stranded RNA (dsRNA) molecules with phosphorylated 5’ ends and 
hydroxylated 3’ ends with two overhanging nucleotides and it contain 20-25 base pairs 
in length (Guo et al., 2013). The structure of siRNA are illustrated below in Figure 
2.5. siRNA are generally produced from long dsRNAs and small hairpin RNAs by a 
catalytic process mediated by Dicer enzyme (Huang et al., 2008). Besides gene 
silencing, siRNA also plays a role in RNAi related pathway via shaping of the 
chromatin structure or by acting as antiviral mechanism (Agrawal et al., 2003). 
siRNAs can be introduced into cells via several methods of delivery such as 
transfection, electroporation, viral-mediated delivery or modified siRNA (Xu and 
Wang, 2015). Nowadays, siRNAs have known as an important tool to validate gene 
function and drug targeting in the post-genomic area. The sensitivity and feasibility of 
the technique to knockdown any gene by using synthetic siRNAs has provided a 
suitable platform for various studies to be carried out (Guo et al., 2013). 
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Figure 2.6: General structure of siRNA. (Adapted from Guo et al., 2013) 
 
 
2.4.2 Gene silencing mechanism using siRNA 
 
RNA interference is valuable in drug development and gene silencing because 
it has high specificity, easy to synthesis, significant effect and less side effects (Davis 
et al., 2010). There are three approaches for RNA interference; endogenous microRNA 
(miRNA), short hairpin RNA (shRNA) and small interfering RNA (siRNA) (Xu and 
Wang, 2015). Among these types, siRNA is the most commonly used RNAi tool for 
introducing a synthetic double-stranded RNA to target a specific mRNA for 
degradation. The interference leads to prevention of protein translation in the cells. 
 
Gene silencing mechanism of siRNA occurred when long double stranded of 
RNA (dsRNA) (e.g: complementary RNAs, hairpin, RNA dependent RNA 
polymerases) is cleaved by endo-ribonuclease enzyme known as Dicer to form a short 
interfering RNA or silencing interfering RNA (siRNA). Dicer enzyme delivers siRNA 
to a group of protein called as RNA-inducing silencing complex (RISC), where the 
catalytic component argonaute (Ago) is able to degrade siRNA into single strand and 
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bind with the target mRNA to induce mRNA cleavage. Further mRNA degradation 
lead to gene silencing or knockdown process (Wittrup and Lieberman, 2015). Figure 
2.7 showed the major steps involved in mechanism of siRNA gene silencing. 
 
 
Figure 2.7: Summary mechanism of siRNA gene silencing. (Adapted from Wittrup, 
A., & Lieberman, J., 2015).  
 
 
 
 
 
 
 
 
 
siRNA-mRNA complex 
siRNA duplex 
dsRNA 
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2.5  Rationale of study 
 
Around 1~ 5 cases in 100,000 people are diagnosed with malignant glioma 
every year. According to World Health Organization (WHO), the most aggressive 
malignant glioma is referred to glioblastoma multiforme which is classified into grade 
IV.  Overexpression of EphA2 was found in malignant glioma cases, and correlated 
with the tumour progression and poor diagnosis of patients. Increasing evidences have 
suggested EphA2 involvement in mediating various biological activities supporting 
tumorigenesis including tumor proliferation, angiogenesis, invasion and metastasis. 
Nowadays, siRNA is known as an important tool to detect the drug targeting and gene 
function in the genomic area. Due to it’s feasibility and sensitivity technique to inhibit 
the expression of a wide range of genes, siRNA has been used as a platform for various 
study to be carried out. In this study, siRNA targeting EphA2 was used to determine 
its efficiency to inhibit EphA2 gene expression in vitro. Furthermore, the effects of 
EphA2 gene silencing on malignant glioma cells proliferation was also determined. 
The findings from this study will help to evaluate the roles of EphA2 in mediating 
proliferation activity of malignant glioma cells. 
 
 
 
 
 
 
